Skip to main content

Table 4 Univariate and Multivariate Cox regression analyses for PFS in Cavitary and Noncavitary Adenocarcinoma patients with EGFR mutations

From: Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Variables Univariate Analysis Multivariate Analysis
HR (95% CI) P HR (95% CI) P
Noncavity vs. Cavity 0.478 (0.271–0.843) 0.011 0.485 (0.261–0.902) 0.022
Female vs. Male 0.846 (0.635–1.127) 0.252 0.793 (0.528–1.190) 0.263
Age > 65 y vs. ≤ 65y 0.790 (0.587–1.062) 0.118 0.691 (0.489–0.976) 0.036
ECOG PS > 1 vs. 0 or 1 0.841 (0.651–1.086) 0.183 0.921 (0.674–1.259) 0.605
Smokers vs. non-smokers 1.124 (0.794–1.591) 0.511 0.919 (0.571–1.480) 0.728
TNM Stage IV vs. stage III + Recurrent 1.022 (0.901–1.160) 0.731 0.972 (0.842–1.122) 0.698
Other EGFR-TKIsa vs. Gefitinib 0.898 (0.666–1.212) 0.483 0.806 (0.574–1.132) 0.214
Tumor size: > 5 cm vs. ≤5 cm 1.886 (1.282–2.775) 0.001 1.741 (1.158–2.619) 0.008
EGFR mutation
 Exon 19 deletion 1.000 (reference)   1.000 (reference)  
 L858R mutation 1.564 (0.988–2.477) 0.056 1.133 (0.659–1.949) 0.651
 Rare mutationsb 1.339 (0.843–2.127) 0.217 1.140 (0.674–1.928) 0.626
  1. Abbreviations: EGFR-TKI epidermal growth factor receptor- tyrosine kinase inhibitor, PFS progression-free survival, HR hazard ratio, CI confidence interval, ECOG PS Eastern Corporation Oncology Group performance status
  2. aIncluding erlotinib, icotinib, afatinib (1 patient), AZD9291 (1 patient)
  3. bincluding EGFR mutations in exons 18 and 20, other than 19DEL and L858R mutations